Last $37.48 USD
Change Today +0.37 / 1.00%
Volume 248.4K
ALR On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Snapshot

Open
$37.11
Previous Close
$37.11
Day High
$37.86
Day Low
$37.11
52 Week High
09/15/14 - $43.00
52 Week Low
04/30/14 - $31.94
Market Cap
3.1B
Average Volume 10 Days
525.2K
EPS TTM
$-1.38
Shares Outstanding
83.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALERE INC (ALR)

alere inc (ALR) Related Businessweek News

View More BusinessWeek News

alere inc (ALR) Details

Alere Inc. provides point-of-care diagnostics and services for cardiology, infectious disease, toxicology, and diabetes in the United States and internationally. Its Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of cardiology, infectious diseases, toxicology, diabetes, oncology, and women’s health, as well as offers connected device technologies. The company’s Health Information Solutions segment offers integrated programs and services focused on wellness, disease and condition management, productivity enhancement, and informatics. This segment’s health improvement programs comprise patient self-testing, condition and case management, women’s and children’s health, and health and wellness programs. Its Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home testing and cholesterol monitoring under the First Check brand name, as well as vaginal gel for the treatment of bacterial vaginosis without antibiotics. Alere Inc. markets its professional diagnostic products to hospitals, reference laboratories, physician offices, and other point-of-care settings through its sales force and distribution networks; health information solutions primarily to commercial and governmental health plans, self-insured employers, government and governmental programs, pharmaceutical companies, and physicians through sales force and channel partners; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

17,600 Employees
Last Reported Date: 03/3/14
Founded in 1981

alere inc (ALR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Vice President and T...
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2013.

alere inc (ALR) Key Developments

Alere Inc. Declares Cash Dividend on Series B Convertible Perpetual Preferred Stock Payable on January 15, 2015

Alere Inc. has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock. The dividend is payable on January 15, 2015 to holders of record of Series B stock at the close of business on January 2, 2015. Such payment will cover the amount of all dividends accrued from October 1, 2014 through December 31, 2014.

Alere Inc. and its Subsidiaries Enter into Sixth Amendment to Secured Credit Agreement

On December 1, 2014, Alere Inc. and certain of its subsidiaries entered into a Sixth Amendment to its secured Credit Agreement, dated as of June 30, 2011, with certain lenders, General Electric Capital Corporation as collateral agent and administrative agent, and certain other agents and arrangers, as previously amended, to permit the company to consummate its previously announced proposed sale of its subsidiary Alere Health, LLC, together with the subsidiaries of Alere Health, to Optum. The Credit Agreement Amendment also provides for, among other things, amendments to the Credit Agreement (1) related to the company's recent sale of its indirect subsidiary BioNote Inc. for a purchase price payable in South Korean Won equal to approximately $45 million based on current exchange rates and (2) to eliminate certain previous conditions to the company's ability to refinance, redeem or otherwise satisfy prior to maturity the company's existing 3% convertible senior subordinated notes due 2016 in the aggregate outstanding principal amount of $150 million. The Credit Agreement Amendment requires the company to use the net cash proceeds of the Alere Health and BioNote dispositions to repay outstanding term loans under the Credit Agreement, provided that the company has the option to use the first $170 million of the net cash proceeds of the sale of Alere Health to repay revolving credit loans outstanding under the Credit Agreement rather than term loans outstanding thereunder. To the extent that the company uses the proceeds of the sale of Alere Health to repay revolving credit loans, the company may reborrow such amounts, subject to compliance with the terms of the Credit Agreement at the time of any such future borrowing; term loan amounts repaid under the Credit Agreement may not be reborrowed. The permissions in the Credit Agreement Amendment related to the sales of Alere Health and BioNote are in addition to the baskets and other permissions for asset dispositions under the relevant negative covenant contained in the Credit Agreement as in effect prior to the Credit Agreement Amendment. The company is required to pay certain amendment fees to the consenting lenders under the Credit Agreement Amendment.

Alere Inc. Appoints Juliet Cunningham as Vice President, Investor Relations

Alere Inc. has appointed Juliet Cunningham as Vice President, Investor Relations. In this newly created role, Cunningham will be responsible for driving communications with the investment community. Cunningham brings nearly two decades of investor relations experience to Alere. She draws from a diverse background including corporate, financial, media and regulatory communications. Prior to joining Alere, Cunningham led corporate investor relations at Lytx, Mitek and Novatel Wireless, and served as managing director at the Blue Shirt Group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $37.48 USD +0.37

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $120.32 USD -0.04
BioMerieux €86.13 EUR -0.07
Getinge AB kr178.90 SEK +1.40
Hill-Rom Holdings Inc $46.04 USD +0.41
Steelcase Inc $18.23 USD +0.16
View Industry Companies
 

Industry Analysis

ALR

Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit www.alere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.